SELLAS Life Sciences Group, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SLS Nasdaq 2836 sellaslifesciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SELLAS Life Sciences Group, Inc.

SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot - Oct 2nd, 2026 1:02 am
SLS Stock Snaps 3-Quarter Winning Streak — Retail Traders Speculate On Buyout, Eye Lease Through 2027 - Oct 1st, 2026 12:01 am
Despite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3 - Sep 30th, 2026 9:45 pm
Can SELLAS Life Sciences (SLS) Turn Early CDK9 Pancreatic Data Into a Durable Oncology Edge? - Sep 30th, 2026 8:08 pm
SELLAS Life Sciences Group (SLS) Stock May Be Trading At A Premium On Fresh Pancreatic Cancer Data - Sep 30th, 2026 9:08 am
SELLAS Life Sciences Group (SLS) Could Be Fully Priced After Fresh SLS009 Pancreatic Data - Sep 30th, 2026 2:09 am
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump? - Sep 29th, 2026 9:47 pm
SLS Stock Slips 3% As Pancreatic Cancer Lab Data Leave REGAL Wait Unanswered - Sep 25th, 2026 2:37 pm
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer - Sep 25th, 2026 11:00 am
SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial - Sep 23rd, 2026 10:59 pm
Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036) | DelveInsight - Sep 21st, 2026 8:31 am
Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next - Sep 20th, 2026 10:37 pm
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally - Sep 17th, 2026 1:21 am
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals - Sep 14th, 2026 10:00 pm
SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck - Sep 14th, 2026 2:47 am
SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts - Sep 9th, 2026 9:03 pm
SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data - Sep 2nd, 2026 7:04 pm
Sellas Gears Up To Present Preclinical SLS009 Data For Pancreatic Cancer At Major Oncology Conference - Sep 2nd, 2026 8:56 am
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer - Sep 2nd, 2026 6:30 am
Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here - Sep 1st, 2026 8:52 am